Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Masarone, Mario ^a   De Renzo, Amalia ^b   La Mura, Vincenzo ^c   Sasso, Ferdinando C ^d   Romano, Marco ^d   Signoriello, Giuseppe ^d   Rosato, Valerio ^d   Perna, Fabiana ^b   Pane, Fabrizio ^b   Persico, Marcello ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

HBV reactivation; Immunosuppression; Non Hodgkin Lymphoma; Occult HBV infection

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HEPATITIS B CORE ANTIBODY; LAMIVUDINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS ISOLATION; VIRUS REACTIVATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DNA, VIRAL; DOXORUBICIN; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; VINCRISTINE; VIRUS ACTIVATION;

EID: 84896695494     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-31     Document Type: Article

References (49)

1. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007, 46:160-170. 10.1016/j.jhep.2006.10.007, 17112622.
2. Marinone C, Mestriner M. HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis 2011, 43S:s49-s56.
3. Gutiérrez-García ML, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. World J Gastroenterol 2011, 17(12):1538-1542. 10.3748/wjg.v17.i12.1538, 3070122, 21472117.
4. Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, Gutkin A, Doucette K, Martin B, Giulivi A. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 2005, 42(4):480-485. 10.1016/j.jhep.2004.11.037, 15763333.
5. Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, Lee NP, Hou JL, Liang R, Lau GK. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005, 42(6):813-819. 10.1016/j.jhep.2005.01.018, 15885351.
6. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, Squadrito G, Pollicino T. Occult hepatitis B virus in liver tissue of individuals withouthepatic disease. J Hepatol 2008, 48(5):743-746. Epub 2008 Feb 13, 10.1016/j.jhep.2008.01.023, 18314221.
7. Persico E, De Renzo A, La Mura V, Bruno S, Masarone M, Torella R, Persico M. Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-HBc positive patients. Gut 2007, 56(10):1470-1471. 10.1136/gut.2007.128777, 2000268, 17872574.
8. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009, 94(7):998-1005. 10.3324/haematol.2009.005819, 2704311, 19454492.
9. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148(7):519-528. 10.7326/0003-4819-148-7-200804010-00008, 2729097, 18378948.
10. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125(6):1742-1749. 10.1053/j.gastro.2003.09.026, 14724827.
11. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47(3):844-853. 10.1002/hep.22106, 18302293.
12. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer 1999, 81(1):69-74. 10.1038/sj.bjc.6690652, 2374347, 10487614.
13. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006, 24(7):1003-1016. 10.1111/j.1365-2036.2006.03081.x, 16984494.
14. Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R, De Renzo A. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002, 99(2):724-725. 10.1182/blood.V99.2.724, 11799967.
15. Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003, 88(11):1296-303.
16. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131(1):59-68. 10.1053/j.gastro.2006.04.015, 16831590.
17. Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011, 83(11):1909-1916. 10.1002/jmv.22199, 21915865.
18. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010, 28(34):5097-5100. 10.1200/JCO.2010.29.7531, 20837949.
19. Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010, 85(3):243-250. 10.1111/j.1600-0609.2010.01474.x, 20491883.
20. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010, 116(20):4769-4776. 10.1002/cncr.25253, 20597091.
21. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009, 50(3):661-662. 10.1002/hep.23190, 19714720.
22. European Association For The Study Of The Liver EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012, 57(1):167-185. European Association For The Study Of The Liver.
23. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A. ItalianAssociation for the Study of the Liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39(5):397-408. 10.1016/j.dld.2006.12.017, 17382608.
24. Harris NL. Principles of the revised European-American lymphoma classification (from the International Lymphoma Study Group). Ann Oncol 1997, 8(Suppl 2):S11-S16. 10.1093/annonc/8.suppl_2.S11, 9341960.
25. Percy C, Van Holten V, Muir C. International classification of diseases for oncology, ICD-O 1990, Geneva: WHO, 2.
26. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999, 17:1244-1214.
27. Lorenz EW. DRGs Working Guidebook 1993 1992, Washington D.C: St. Anthony Pub, ISBN: 1563291037, 9781563291036.
28. Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, Madonna E, Cotichini R, Barbui A, De Renzo A, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, Rapicetta M. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006, 91(4):554-557.
29. Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E. Hepatitis B virus related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008, 93(6):951-952. 10.3324/haematol.12557, 18515881.
30. Lok ASF. Occult hepatitis B virus infection: diagnosis, implications and management?. J Gastroenterol Hepatol 2004, 19:S114-S117.
31. Matsumoto C, Nishioka K, Oguchi T, Mitsunaga S, Nojiri N, Tadokoro K, Juji T. Detection and quantitation of HBV DNA by semi-Nested PCR in donated blood: comparison with HBV serological markers. J Virol Methods 1997, 66:61-69. 10.1016/S0166-0934(97)00037-2, 9220391.
32. Iizuka H, Ohmura K, Ishijima A, Satoh K, Tanaka T, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M. Correlation between anti-HBc titers and HBV-DNA in blood units without HBsAg. Vox Sang 1992, 63:107-111. 10.1111/j.1423-0410.1992.tb02495.x, 1441302.
33. Douglas DD, Taswell HF, Rakela J, Rabe D. Absence of hepatitis B virus DNA detected by polymerase chain reaction in blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of Hepatitis B serologic markers. Transfusion 1993, 33:212-216.
34. Weinberger KM, Bauer T, Bohm S, Jilg W. High genetic variability of the group-specific-a-determinant of hepatitis B surface antigen and the corresponding fragment of the viral polymerase in chronic virus lacking detectable HBsAg in serum. J Gen Virol 2000, 81:1156-1174.
35. Hollinger FB. Hepatitis B, virus infection and transfusionmedicine: science and the occult. Transfusion 2008, 48(5):1001-1026.
36. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003, 43:696-704.
37. Kleinman SH, Strong DM, Tegtmeier GG, Holland PV, Gorlin JB, Cousins C, Chiacchierini RP, Pietrelli LA. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 2005, 45:1247-1257.
38. Linauts S, Saldanha J, Strong DM. PRISM hepatitis B surface antigen detection of hepatits B virus minipool nucleic acid testing yield samples. Transfusion 2008, 48:1376-1382.
39. Chevrier MC, St-Louis M, Perreault J, Caron B, Castilloux C, Laroche J, Delage G. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. Transfusion 2007, 47:1794-1802.
40. O'Brien SF, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR, Vamvakas EC. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion 2007, 47:1809-1815.
41. Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999, 107:186-195. 10.1046/j.1365-2141.1999.01665.x, 10520040.
42. Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 2002, 100:2637-2641. 10.1182/blood-2002-03-0798, 12239179.
43. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ, German Red Cross NAT Study Group Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008, 48:1558-1566. German Red Cross NAT Study Group.
44. Launay O, Masurel J, Servant-Delmas A, Basse-Guérineau AL, Méritet JF, Laperche S, Sogni P, Rosenberg AR. High levels of serum hepatitis B virus DNA in patients with " anti-HBc alone" : role of HBsAg mutants. J Viral Hepat 2011, 18:721-29. 10.1111/j.1365-2893.2011.01482.x, 21914087.
45. Umemura T, Tanaka E, Kiyosawa K, Kumada H, Japan de novo Hepatitis B Research Group Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008, 47(5):e52-e56. 10.1086/590968, 18643758, Japan de novo Hepatitis B Research Group.
46. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010, 89(3):255-262. 10.1007/s00277-009-0806-7, 19697028.
47. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27(4):605-611.
48. Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010, 116(1):115-112.
49. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011, 22(5):1170-1178. 10.1093/annonc/mdq583, 3082161, 21115603.